Remedy Plan Therapeutics has appointed Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer as the company transitions into the clinic with its lead asset, RPT1G, a next-generation NAMPT inhibitor now in a Phase 1 study for relapsed/refractory AML and higher-risk MDS (NCT07107126). The dual finance–business remit and timing signal a coordinated push to align capital strategy, partnering, and clinical execution around a mechanism that has long intrigued oncology but stumbled on toxicity.
The strategic question is whether a modulation-first approach to NAMPT inhibition can rehabilitate a target class largely defined by on-target adverse events and deliver a commercially viable profile in hematologic malignancies where new mechanisms are urgently needed. Remedy Plan positions RPT1G as a selective small molecule employing “hyperbolic inhibition,” designed to dial down, rather than shut off, NAMPT activity—aiming to preserve healthy-cell metabolism while exploiting tumor metabolic dependencies. If realized clinically, that framing moves the program out of the penalty box that has historically constrained NAMPT and into combination-friendly territory where tolerability is a gatekeeper to adoption.
This matters now because the AML/MDS landscape is at an inflection point. After rapid uptake of venetoclax-based regimens, the field is reassessing recent setbacks across antibody and innate immunity approaches and recalibrating expectations for durability and real-world tolerability. A metabolically targeted agent with manageable safety could find a role in specific molecular or phenotypic niches and, crucially, as a partner in doublets or triplets that extend benefit without compounding myelosuppression. For HCPs, early clarity on pharmacodynamic markers—such as NAD pathway readouts and peripheral biomarker kinetics—will be essential to guide dosing, manage risk, and justify combinations. For payers, where inpatient utilization and supportive care drive cost in AML/MDS, a therapy that maintains dose intensity without excessive resource burden could earn favorable positioning, provided outcomes are credibly differentiated versus contemporary backbones.
Marango’s background blends capital markets fluency with transaction experience across small-molecule oncology, including leadership through a merger process and multiple strategic financings. That profile suggests an agenda beyond routine treasury: sharpening the company’s partnering story, structuring non-dilutive capital around discrete milestones, and potentially segmenting optionality across oncology and adjacent indications in autoimmune and metabolic disease where NAMPT biology also plays. With trial initiation underway, the near-term objective will be to translate a mechanistic narrative into decision-grade human data that can catalyze either a co-development alliance or a crossover financing under tighter diligence standards.
The appointment also reflects a broader sector pattern. Clinical-stage biotechs are consolidating CFO and CBO roles to navigate a funding environment defined by selective crossover participation, royalty-capital alternatives, and program-focused M&A. In parallel, interest in metabolism-targeted oncology is re-emerging as companies refine target engagement, dosing paradigms, and biomarker strategies to escape the toxicity traps of earlier generations. Regulatory dynamics in hematology continue to favor robust confirmatory packages over single-arm signals, increasing the premium on translational rigor and early combination planning.
The next six to twelve months will determine whether Remedy Plan can de-risk NAMPT clinically while building a partnership-ready dossier. The critical readouts will be evidence of controlled target modulation, a tolerability profile compatible with frontline backbones, and a plausible patient-selection hypothesis. If those pieces align, does NAMPT finally step out of the shadows as a combinable metabolic lever in AML/MDS—and can Remedy Plan convert that scientific turn into the capital and alliances needed to scale quickly before competitors reclaim the space?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
